Adjuvant treatment | 191 |
Africa | 28 |
And clinical outcomes | 115 |
Artificial intelligence | 261, 262 |
Automated breast ultrasound | 311 |
Axillary lymph node dissection | 229, 318 |
Axillary lymph node metastasis | 115 |
Axillary surgery | 318 |
Axillary treatment | 229 |
BCS | 99 |
Benign breast lesions | 166 |
Bioinformatics | 45 |
Biomarkers | 45 |
Biopsy | 1, 76 |
Body mass index | 210 |
BRCA1 | 235 |
BRCA1/2 | 55 |
BRCA2 | 235 |
Breast | 1, 253 |
Breast cancer | 28, 34, 45, 55, 70, 76, 85, 99, 121, 128, 159, 191, 201, 229, 235, 274, 297, 325, 331 |
Breast cancer management | 186 |
Breast cancer risk | 222, 267 |
Breast cancer screenings | 279 |
Breast conserving surgery | 287, 331 |
Breast hematoma | 257 |
Breast imaging | 99, 262, 304 |
Breast magnetic resonance imaging | 140 |
Breast neoplasm | 177 |
Breast pain | 210 |
Breast reconstruction | 172 |
Breast self-examination | 215 |
Breast-conserving surgery | 318 |
Breast | 335 |
Cancer | 1, 92 |
Capecitabine | 128 |
CDH1/PALB2 | 55 |
Chemoprevention | 267 |
Chemoresistance | 45 |
Chemotherapy | 186 |
Clinicopathologic characteristics | 115 |
Complex decongestive treatment | 34 |
Complex sclerosing lesion | 166 |
Conformity | 92 |
Conserving therapy | 121 |
Cosmetic outcome | 287 |
CYSLTR1 | 148 |
Diagnostic techniques | 262 |
Ductal carcinoma in situ | 140, 253 |
Early breast cancer | 229 |
Early detection of cancer | 215 |
Early diagnosis | 222 |
Elderly women | 201 |
F-18 FDG | 159 |
Fear | 70 |
Genetic testing | 55 |
Genomic profiling | 235 |
Goldilocks mastectomy | 172 |
Gynaecomastia | 304 |
Handheld ultrasound | 311 |
HER2/neu receptor | 128 |
Homogeneity | 92 |
Immigrant | 222 |
International survey | 201 |
Interventional | 262 |
Ki-67 | 274 |
Kinesio-taping | 34 |
Lapatinib | 128 |
Leukotriene | 148 |
Liposarcoma | 335 |
Local relapse | 191 |
Locoregional treatment | 110 |
Low level laser therapy | 34 |
Lymph node | 253 |
Lymphedema | 34 |
Magnetic resonance imaging | 1, 85, 335 |
Male breast | 304 |
Mammography | 70, 76, 85, 140, 279 |
Manual lymphatic drainage | 34 |
Mastalgia | 210 |
Mastectomy | 92, 121, 134 |
Mechanical support | 210 |
Mediators of inflammation | 148 |
Metastasis | 128, 191, 274 |
Metastatic breast carcinoma | 110 |
Molecular subtypes | 186 |
Navigation | 28 |
Neoadjuvant chemotherapy | 45, 99, 159 |
Nipple areola complex | 172 |
Nursing | 215 |
Oligometastatic disease | 110 |
Oncoplastic breast surgery | 261 |
Oncotype DX recurrence score | 325 |
Operational cost | 311 |
Oral anticoagulant | 257 |
Pandemic | 177 |
Patient | 177 |
Patient care | 28 |
Phyllodes tumor | 191 |
Pleomorphic | 335 |
Population study | 235 |
PREDICT tool | 325 |
Preventive behaviors | 279 |
Psycho-oncology | 297 |
Pure tubular breast carcinoma | 115 |
Pyoderma gangrenosum | 331 |
Quality of life | 121, 210 |
Quality-of-life | 287 |
Radial scar | 76, 166 |
Radiologist | 311 |
Radiology | 262 |
Radiotherapy | 92, 287 |
Reassurance | 210 |
Reconstruction | 121 |
Recurrence | 85, 191 |
Regressive changes | 140 |
Resilience | 297 |
Sclerosant | 134 |
Screening | 201, 262 |
SCUBE2 | 45 |
Senologic international society | 201 |
Sentinel lymph node biopsy | 186, 229, 318 |
Seroma | 134, 318 |
Silver rod localization | 99 |
Spiculated lesion | 166 |
Spiritual well-being | 297 |
Src inhibitors | 267 |
Supportive care | 297 |
Surgery | 186 |
Surgical planning | 261 |
Survival | 110 |
SUVmax | 159 |
Systemic therapy | 110 |
TAILORx risk categorization | 325 |
Theranostics | 262 |
Therapeutic | 177 |
Time savings | 311 |
TP53/PTEN | 55 |
Treatment | 201, 257 |
Triple negative breast cancer | 274 |
Triple-negative breast cancer | 148 |
Ultrasound | 76, 85, 140 |
Upgrade | 76 |
Women | 215 |
Worry | 279 |